21293-29-8
21293-29-8 結(jié)構(gòu)式
基本信息
脫落酸
S-誘抗素
5-(1-羥基-2,6,6-三甲基-4-氧-2-環(huán)己-1-烯基-3-甲基-2,4-戊二烯酸
脫落素Ⅱ
休眠酸
脫落酸
ABA,休眠素
脫落酸(ABA)
落葉酸
(+)-脫落酸
(S)-5-(1-羥基-4-氧代-2,6,6-三甲基-2-環(huán)己烯-1-基)-3-甲基-(2Z,4E)-戊二烯酸
ABA
ABK
(+)-ABSCISIC ACID
ABSCISIC ACID
ABSCISIC ACID, (+)-
ABSCISIN
(+)-CIS,TRANS-ABSCISIC ACID
DORMIN
[S]-5-[1-HYDROXY-2,6,6-TRIMETHYL-4-OXOCYCLOHEX-2-EN-1-YL]-3-METHYL-[2Z,4E]-PENTADIENOIC ACID
S-(+)-ABA
S-ABA
(S)-(+)-ABSCISIC ACID
(+)-abscisinii
(+)-cis-abscisicacid
(s-(z,e))-methyl
abscisinii
acideabscisique
cis-abscisicacid
dormin(abscissionfactor)
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
常見問題列表
(+)-脫落酸純品為無色晶體。熔點160~161℃。120℃升華，分配系數(shù)為1.8(電中性形式)、0.94(離子形式)。相對密度1.21。在水中的溶解度為3102mg/L(pH 4)。旋光率[a]20D = +409.97R(20℃在乙醇中,10.1mg/mL)。pKa為4.61。溶于氯仿、丙酮、乙酸乙酯和乙醚。微溶于苯和水。紫外最大吸收波長(甲醇)252nm。
大鼠急性經(jīng)口LD50 >5000mg/kg。大鼠急性經(jīng)皮LD50>5000mg/kg。大鼠吸入LC50(4h)>5.1mg/L。NOEL:(90d)大鼠每天2000mg/L;(3周)大鼠經(jīng)皮1000mg/kg; NOAEL1000mg/(kg·d)。
(+)-脫落酸是一種植物生長調(diào)節(jié)劑，具有誘導(dǎo)植物休眠、抑制種子萌發(fā)和植物生長、刺激氣孔關(guān)閉等多方面的生理作用。
(+)-脫落酸通過如下反應(yīng)制得：
|
Human Endogenous Metabolite
|
In Arabidopsis cell cultures, Abscisic acid ((S)-(+)-Abscisic acid; 10 μM) simultaneously induces rapid alkalinization of the medium and plasma membrane depolarization.
Abscisic acid (10 μM) increases Ca
2+
in cytosol of Arabidopsis cell suspension. Abscisic acid does not inhibit proton pumping directly but through an increase in cytosolic Ca
2+
.
Lanthionine synthetase C-like 2 (LANCL2) is the natural receptor for Abscisic acid. Abscisic acid, both at the organism levels and in specific muscle cells ex vivo, increases both glucose and fatty acid metabolism in the mitochondria, increases glycogen synthesis, activates PI3K independently of insulin and promotes GLUT4 translocation to the cell membrane.
Abscisic acid (orally; 0.125?μg/kg/day; for 12 weeks) improves glycemic control.
Abscisic acid (orally; 0.125?μg/kg/day; for 12 weeks) results in significantly lower levels of TNF, MCP-1 and IL-6 in the DIO model. Abscisic acid increases metabolic activity in skeletal muscle.
| Animal Model: | Diet-induced obesity (DIO) mice at 4 weeks of age |
| Dosage: | 0.125?μg/kg |
| Administration: | Orally; daily; for 12 weeks |
| Result: | Improved glycemic control in a diet-induced model of obesity |